KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Average (2020 - 2025)

Recursion Pharmaceuticals' Equity Average history spans 6 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 39.66% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 39.66%, while the annual FY2025 figure was $1.1 billion, 44.55% up from the prior year.
  • Equity Average reached $1.1 billion in Q4 2025 per RXRX's latest filing, up from $983.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.1 billion in Q4 2025 to a low of -$219.7 million in Q1 2021.
  • Average Equity Average over 5 years is $553.2 million, with a median of $479.2 million recorded in 2022.
  • Peak YoY movement for Equity Average: skyrocketed 463.6% in 2021, then crashed 33.51% in 2022.
  • A 5-year view of Equity Average shows it stood at $571.0 million in 2021, then decreased by 23.48% to $436.9 million in 2022, then increased by 3.15% to $450.7 million in 2023, then skyrocketed by 72.99% to $779.7 million in 2024, then surged by 39.66% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Equity Average are $1.1 billion (Q4 2025), $983.0 million (Q3 2025), and $926.5 million (Q2 2025).